After weathering the COVID-19 pandemic for more than a year, Taiwan has since early last month been hit by a wave of local infections. Before then, few people were concerned about vaccines, but the issue has suddenly become the focus of public attention. The urgency of obtaining vaccines has been much discussed, but many do not understand the peculiarities of the vaccine industry, or international vaccine supply and demand amid a pandemic.
Taiwan’s epidemic prevention policy over the past four decades has been oriented toward public health — from the control and prevention of hepatitis B in the early 1980s and the local development of an avian influenza vaccine in the early 2000s to the development of enterovirus vaccines — with emergency situations receiving temporary policy support, but support for vaccine development ebbed as the epidemics subsided.
Over the past decade, there have only been a handful of domestic vaccine manufacturers, but they have played an important role in public health by supplying influenza vaccines. Two domestic enterovirus vaccines even entered phase 3 clinical trials.
Taiwan’s excellent performance at disease prevention since the beginning of last year had given Taiwanese peace of mind as they went about their daily lives, and the recent outbreak has led to the public demanding that the government obtain an adequate supply of vaccine doses.
The market for COVID-19 vaccines is still a seller’s market, with each major international player — Europe and the US on the one hand, and China and Russia on the other — following its own approach. Taiwan has struggled to find a vaccine source in the European and US supply chain.
However, those not involved in the negotiations cannot understand the hardships faced by officials. Once the outbreak has been effectively controlled and the nation’s vaccine needs softened, the government should establish a vaccine industry policy based on national security.
The Taiwanese vaccine market, with a population of 24 million, is not large enough to support an internationally competitive vaccine industry. Even in South Korea, whose population is more than double Taiwan’s, vaccines at this stage are produced by contract manufacturers for international pharmaceutical companies.
Local vaccine manufacturers Medigen Vaccine Biologics and United Biomedical have conducted phase 2 clinical trials — some talk of them as phase 2/3 clinical trials — of a COVID-19 vaccine, with more than 3,000 participants. The nation would hopefully give them heartfelt support to avoid relying on foreign sources for vaccines in a future pandemic.
The vaccine industry must be positioned as one of the industries crucial to national security, and government policies must provide the industry with subsidies or tax incentives, as well as a guarantee of at least one-third to one-half of the domestic market to support normal production.
Regarding the need for vaccines, as the nation seeks sources, it should also pay attention to the nature of the vaccine industry.
The process of manufacturing vaccines at any pharmaceutical company follows a specific plan and timetable. There are basic elements that must not be ignored, such as quantity, batch number, batch production records, the original quality control inspection and qualification documents, and the cold chain records of the transportation process, among others.
Close cooperation with the Central Epidemic Command Center is still required after a vaccine shipment arrives at an airport, in the subsequent transportation, storage, distribution and administration stages. Perhaps a batch-by-batch emergency approach could be adopted, instead of being bound by administrative details such as, for example, the applicant’s qualifications.
At this time of urgent need, the Food and Drug Administration ensures that the vaccine documentation confirms the quality and safety of the doses in accordance with the Regulations of the Lot Release Procedures for Biologics (生物藥品檢驗封緘作業辦法). Because of the urgency involved, the release procedure — including testing items such as sterility and acute toxicity — should be synchronized with the distribution and transportation of the doses.
Although the release of a vaccine lot must comply with regulations, its execution should be more flexible in these extraordinary times. The batch quality control release document issued by the original manufacturer is sufficient to confirm the quality of a batch, and the inspection typically conducted only drags out the administrative process.
The release policy should be governed by a different mindset, and a batch-by-batch approach that fast-tracks the validation process should be adopted to promote a timely vaccine supply.
Huang Weng-foung is an adjunct professor at National Yang Ming Chiao Tung University and a former director-general of the Ministry of Health and Welfare’s Bureau of Pharmaceutical Affairs.
Translated by Perry Svensson
Is a new foreign partner for Taiwan emerging in the Middle East? Last week, Taiwanese media reported that Deputy Minister of Foreign Affairs Francois Wu (吳志中) secretly visited Israel, a country with whom Taiwan has long shared unofficial relations but which has approached those relations cautiously. In the wake of China’s implicit but clear support for Hamas and Iran in the wake of the October 2023 assault on Israel, Jerusalem’s calculus may be changing. Both small countries facing literal existential threats, Israel and Taiwan have much to gain from closer ties. In his recent op-ed for the Washington Post, President William
Taiwan-India relations appear to have been put on the back burner this year, including on Taiwan’s side. Geopolitical pressures have compelled both countries to recalibrate their priorities, even as their core security challenges remain unchanged. However, what is striking is the visible decline in the attention India once received from Taiwan. The absence of the annual Diwali celebrations for the Indian community and the lack of a commemoration marking the 30-year anniversary of the representative offices, the India Taipei Association and the Taipei Economic and Cultural Center, speak volumes and raise serious questions about whether Taiwan still has a coherent India
A stabbing attack inside and near two busy Taipei MRT stations on Friday evening shocked the nation and made headlines in many foreign and local news media, as such indiscriminate attacks are rare in Taiwan. Four people died, including the 27-year-old suspect, and 11 people sustained injuries. At Taipei Main Station, the suspect threw smoke grenades near two exits and fatally stabbed one person who tried to stop him. He later made his way to Eslite Spectrum Nanxi department store near Zhongshan MRT Station, where he threw more smoke grenades and fatally stabbed a person on a scooter by the roadside.
Recent media reports have again warned that traditional Chinese medicine pharmacies are disappearing and might vanish altogether within the next 15 years. Yet viewed through the broader lens of social and economic change, the rise and fall — or transformation — of industries is rarely the result of a single factor, nor is it inherently negative. Taiwan itself offers a clear parallel. Once renowned globally for manufacturing, it is now best known for its high-tech industries. Along the way, some businesses successfully transformed, while others disappeared. These shifts, painful as they might be for those directly affected, have not necessarily harmed society
RSS